Movement Alert｜Twist Bioscience Rises 6.12% in Regular Trading, Breaking Through Analyst $90 Target Price on Continued Rebound

Market Focus06-25 22:07

On June 25, Twist Bioscience rose 6.12% in regular trading, reaching $93.57 per share with turnover of $23.44 million, breaking above the $90 price target previously set by Canaccord Genuity.

The rally extends a sharp recovery from dilution concerns triggered when the company filed a shelf registration statement with the SEC covering potential issuance of up to $200 million in common stock under an at-the-market program. The filing initially sent shares down over 5%. However, sentiment quickly reversed after Canaccord Genuity initiated coverage with a Buy rating and $90 target price — significantly above the consensus target of $73.12. Multiple other investment banks had also upgraded ratings following Q2 results in early May, with Leerink raising its rating to Outperform and lifting its target to $70.

Fundamentally, Twist Bioscience reported Q2 revenue of $110.7 million beating estimates, issued Q3 guidance of $114-115 million above the $111.3 million consensus, and expects adjusted EBITDA breakeven by fiscal Q4, supporting the bullish institutional outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168915675?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168915675","market":"us","top_or_hot":-1,"title":"Movement Alert｜Twist Bioscience Rises 6.12% in Regular Trading, Breaking Through Analyst $90 Target Price on Continued Rebound","media":"Market Focus","content":"<p><p>On June 25, Twist Bioscience rose 6.12% in regular trading, reaching $93.57 per share with turnover of $23.44 million, breaking above the $90 price target previously set by Canaccord Genuity.</p><p>The rally extends a sharp recovery from dilution concerns triggered when the company filed a shelf registration statement with the SEC covering potential issuance of up to $200 million in common stock under an at-the-market program. The filing initially sent shares down over 5%. However, sentiment quickly reversed after Canaccord Genuity initiated coverage with a Buy rating and $90 target price — significantly above the consensus target of $73.12. Multiple other investment banks had also upgraded ratings following Q2 results in early May, with Leerink raising its rating to Outperform and lifting its target to $70.</p><p>Fundamentally, Twist Bioscience reported Q2 revenue of $110.7 million beating estimates, issued Q3 guidance of $114-115 million above the $111.3 million consensus, and expects adjusted EBITDA breakeven by fiscal Q4, supporting the bullish institutional outlook.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Twist Bioscience Rises 6.12% in Regular Trading, Breaking Through Analyst $90 Target Price on Continued Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Twist Bioscience Rises 6.12% in Regular Trading, Breaking Through Analyst $90 Target Price on Continued Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, Twist Bioscience rose 6.12% in regular trading, reaching $93.57 per share with turnover of $23.44 million, breaking above the $90 price target previously set by Canaccord Genuity.</p><p>The rally extends a sharp recovery from dilution concerns triggered when the company filed a shelf registration statement with the SEC covering potential issuance of up to $200 million in common stock under an at-the-market program. The filing initially sent shares down over 5%. However, sentiment quickly reversed after Canaccord Genuity initiated coverage with a Buy rating and $90 target price — significantly above the consensus target of $73.12. Multiple other investment banks had also upgraded ratings following Q2 results in early May, with Leerink raising its rating to Outperform and lifting its target to $70.</p><p>Fundamentally, Twist Bioscience reported Q2 revenue of $110.7 million beating estimates, issued Q3 guidance of $114-115 million above the $111.3 million consensus, and expects adjusted EBITDA breakeven by fiscal Q4, supporting the bullish institutional outlook.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1168915675","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168915675","pubTimestamp":1782396466,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, Twist Bioscience rose 6.12% in regular trading, reaching $93.57 per share with turnover of $23.44 million, breaking above the $90 price target previously set by Canaccord Genuity.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"走势提示|Twist Bioscience常规交易涨6.12%持续反弹突破分析师90美元目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"On June 25, Twist Bioscience rose 6.12% in regular trading, reaching $93.57 per share with turnover of $23.44 million, breaking above the $90 price target previously set by Canaccord Genuity.The rally extends a sharp recovery from dilution concerns triggered when the company filed a shelf registration statement with the SEC covering potential issuance of up to $200 million in common stock under an at-the-market program. The filing initially sent shares down over 5%. However, sentiment quickly reversed after Canaccord Genuity initiated coverage with a Buy rating and $90 target price — significantly above the consensus target of $73.12. Multiple other investment banks had also upgraded ratings following Q2 results in early May, with Leerink raising its rating to Outperform and lifting its target to $70.Fundamentally, Twist Bioscience reported Q2 revenue of $110.7 million beating estimates, issued Q3 guidance of $114-115 million above the $111.3 million consensus, and expects adjusted EBITDA breakeven by fiscal Q4, supporting the bullish institutional outlook.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168915675","isCrawlerRequest":true}